home / stock / lyra / lyra articles
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 0.18% to 38,7...
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 0.25% to 38,772.28 whil...
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra"...
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing inn...
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnol...
News, Short Squeeze, Breakout and More Instantly...
Lyra Therapeutics Inc. Company Name:
LYRA Stock Symbol:
NASDAQ Market:
Lyra Therapeutics Inc. Website:
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced th...
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advancing In-House Manufacturing Capabilities to ...